<p>景顺投资管理有限公司在最近向美国证券交易委员会提交的 13F 表格中披露，第二季度将其在 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）中的持股减少了 33.3%。该公司在此期间售出了 285,452 股后，持有 571,549 股 Axsome Therapeutics 的股票。到最近的报告期末，景顺投资管理有限公司持有的 Axsome Therapeutics 股份约占 1.15%，价值 59,664,000 美元。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 警报：</p>
<ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
<p>其他机构投资者最近也增加或减少了在该公司的股份。凯通国际资产管理有限公司在第一季度购买了价值约 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度购买了价值 31,000 美元的 Axsome Therapeutics 新头寸。AlphaQuest LLC 在第一季度收购了价值 38,000 美元的 Axsome Therapeutics 新股份。BI 资产管理基金经理公司在第一季度购买了价值约 47,000 美元的 Axsome Therapeutics 新股份。最后，Ameritas Advisory Services LLC 在第二季度购买了价值约 77,000 美元的 Axsome Therapeutics 新股份。对冲基金和其他机构投资者持有该公司 81.49% 的股票。</p>
<h2>分析师评级变动</h2>
<p>AXSM 已经成为几份研究分析师报告的主题。摩根士丹利在 11 月 4 日的研究报告中将 Axsome Therapeutics 的目标价格从 194.00 美元上调至 196.00 美元，并给予该股票 “超配” 评级。Guggenheim 在 11 月 4 日的研究报告中将 Axsome Therapeutics 的目标价格从 200.00 美元上调至 205.00 美元，并给予该公司 “买入” 评级。加拿大皇家银行在 11 月 4 日的研究报告中将 Axsome Therapeutics 的目标价格从 189.00 美元上调至 198.00 美元，并给予该股票 “跑赢大盘” 评级。瑞穗在 11 月 6 日的报告中将 Axsome Therapeutics 的目标价格从 200.00 美元上调至 202.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Axsome Therapeutics 的 “卖出（d-）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，十六位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价格为 179.88 美元。</p>
<ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p><strong>查看我们对 AXSM 的最新股票分析</strong></p>
<h2>Axsome Therapeutics 的内部活动</h2>
<p>在 Axsome Therapeutics 的其他新闻中，首席运营官 Mark L. Jacobson 在 9 月 22 日的交易中出售了 10,000 股公司的股票。该股票以 115.96 美元的平均价格出售，总交易额为 1,159,600.00 美元。此次出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Herriot Tabuteau 在 12 月 4 日的交易中出售了 10,558 股公司的股票。该股票以 148.18 美元的平均价格出售，总交易额为 1,564,484.44 美元。出售完成后，首席执行官持有 7,229 股公司的股票，价值 1,071,193.22 美元。此次交易代表其持股减少了 59.36%。此次出售的披露信息可在 SEC 备案中找到。在过去 90 天内，内部人士已出售 407,959 股公司股票，价值 52,645,040 美元。公司内部人士持有该公司 22.30% 的股票。</p>
<h2>Axsome Therapeutics 价格表现</h2>
<ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
<p>AXSM 的股票在周四以 149.26 美元开盘。该公司的债务与股本比率为 1.66，速动比率为 1.50，流动比率为 1.57。Axsome Therapeutics, Inc.的 52 周低点为 75.56 美元，52 周高点为 152.94 美元。该公司的 50 日简单移动平均线为 136.66 美元，200 日简单移动平均线为 119.76 美元。该公司的市值为 75.2 亿美元，市盈率为-31.96，贝塔值为 0.48。</p>
<p>Axsome Therapeutics（NASDAQ:AXSM - 获取免费报告）最近在 11 月 3 日发布了季度财报。该公司报告本季度每股收益为（0.94 美元），低于市场共识预期的（0.82 美元）12 美分。Axsome Therapeutics 的净利润率为-40.90%，股本回报率为-277.31%。该公司本季度的收入为 1.7099 亿美元，而分析师预期为 1.6296 亿美元。该公司的收入同比增长 63.2%。平均而言，股票研究分析师预计 Axsome Therapeutics, Inc.在本年度将发布-2.79 的每股收益。</p>
<h2>关于 Axsome Therapeutics</h2>
<p>（免费报告）</p>
<p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利安非特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的白天过度嗜睡的药物。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过 Axsome Therapeutics</li>
<li>股息王宝洁在财报后疲软时值得买入</li>
<li>市场动能：3 只有望大幅突破的股票</li>
<li>成长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

景顺投资管理

<p>景顺投资管理在第二季度将其在 Axsome Therapeutics, Inc.的持股减少了 33.3%，出售了 285,452 股，保留了价值 5966 万美元的 571,549 股。其他机构投资者也调整了他们的持仓。分析师对 AXSM 的评级不一，普遍共识为 “适度买入”，平均目标价为 179.88 美元。内部人士最近出售了大量股份。Axsome 的股票开盘价为 149.26 美元，市值为 75.2 亿美元。该公司报告第三季度收入为 1.7099 亿美元，同比增长 63.2%，但未达到每股收益预期</p>

<p>Invesco Ltd. trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 33.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 571,549 shares of the company's stock after selling 285,452 shares during the period. Invesco Ltd. owned about 1.15% of Axsome Therapeutics worth $59,664,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>景顺投资管理有限公司在最近向美国证券交易委员会提交的 13F 表格中披露，第二季度将其在 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）中的持股减少了 33.3%。该公司在此期间售出了 285,452 股后，持有 571,549 股 Axsome Therapeutics 的股票。到最近的报告期末，景顺投资管理有限公司持有的 Axsome Therapeutics 股份约占 1.15%，价值 59,664,000 美元。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 警报：</p>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
</div><p>Other institutional investors also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $25,000. Quantbot Technologies LP purchased a new position in Axsome Therapeutics in the first quarter valued at $31,000. AlphaQuest LLC acquired a new stake in Axsome Therapeutics in the first quarter valued at $38,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Axsome Therapeutics during the 1st quarter worth about $47,000. Finally, Ameritas Advisory Services LLC purchased a new stake in Axsome Therapeutics during the 2nd quarter worth about $77,000. Hedge funds and other institutional investors own 81.49% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也增加或减少了在该公司的股份。凯通国际资产管理有限公司在第一季度购买了价值约 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度购买了价值 31,000 美元的 Axsome Therapeutics 新头寸。AlphaQuest LLC 在第一季度收购了价值 38,000 美元的 Axsome Therapeutics 新股份。BI 资产管理基金经理公司在第一季度购买了价值约 47,000 美元的 Axsome Therapeutics 新股份。最后，Ameritas Advisory Services LLC 在第二季度购买了价值约 77,000 美元的 Axsome Therapeutics 新股份。对冲基金和其他机构投资者持有该公司 81.49% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>AXSM has been the topic of several research analyst reports. Morgan Stanley raised their target price on Axsome Therapeutics from $194.00 to $196.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 4th. Guggenheim increased their price target on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 4th. Royal Bank Of Canada boosted their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, November 4th. Mizuho upped their target price on shares of Axsome Therapeutics from $200.00 to $202.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $179.88.</p>
<div class="lb-trans"><p>AXSM 已经成为几份研究分析师报告的主题。摩根士丹利在 11 月 4 日的研究报告中将 Axsome Therapeutics 的目标价格从 194.00 美元上调至 196.00 美元，并给予该股票 “超配” 评级。Guggenheim 在 11 月 4 日的研究报告中将 Axsome Therapeutics 的目标价格从 200.00 美元上调至 205.00 美元，并给予该公司 “买入” 评级。加拿大皇家银行在 11 月 4 日的研究报告中将 Axsome Therapeutics 的目标价格从 189.00 美元上调至 198.00 美元，并给予该股票 “跑赢大盘” 评级。瑞穗在 11 月 6 日的报告中将 Axsome Therapeutics 的目标价格从 200.00 美元上调至 202.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Axsome Therapeutics 的 “卖出（d-）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，十六位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价格为 179.88 美元。</p>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on AXSM</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AXSM 的最新股票分析</strong></p>
</div><h2>Insider Activity at Axsome Therapeutics</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 的内部活动</h2>
</div><p>In other Axsome Therapeutics news, COO Mark L. Jacobson sold 10,000 shares of the company's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $115.96, for a total transaction of $1,159,600.00. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Herriot Tabuteau sold 10,558 shares of the firm's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $148.18, for a total transaction of $1,564,484.44. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company's stock, valued at $1,071,193.22. This trade represents a 59.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 407,959 shares of company stock valued at $52,645,040 in the last 90 days. Company insiders own 22.30% of the company's stock.</p>
<div class="lb-trans"><p>在 Axsome Therapeutics 的其他新闻中，首席运营官 Mark L. Jacobson 在 9 月 22 日的交易中出售了 10,000 股公司的股票。该股票以 115.96 美元的平均价格出售，总交易额为 1,159,600.00 美元。此次出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Herriot Tabuteau 在 12 月 4 日的交易中出售了 10,558 股公司的股票。该股票以 148.18 美元的平均价格出售，总交易额为 1,564,484.44 美元。出售完成后，首席执行官持有 7,229 股公司的股票，价值 1,071,193.22 美元。此次交易代表其持股减少了 59.36%。此次出售的披露信息可在 SEC 备案中找到。在过去 90 天内，内部人士已出售 407,959 股公司股票，价值 52,645,040 美元。公司内部人士持有该公司 22.30% 的股票。</p>
</div><h2>Axsome Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 价格表现</h2>
</div><ul>
<li>Why this is an Awesome Time to Buy Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
</div><p>Shares of AXSM opened at $149.26 on Thursday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. Axsome Therapeutics, Inc. has a fifty-two week low of $75.56 and a fifty-two week high of $152.94. The firm has a 50-day simple moving average of $136.66 and a 200-day simple moving average of $119.76. The company has a market capitalization of $7.52 billion, a price-to-earnings ratio of -31.96 and a beta of 0.48.</p>
<div class="lb-trans"><p>AXSM 的股票在周四以 149.26 美元开盘。该公司的债务与股本比率为 1.66，速动比率为 1.50，流动比率为 1.57。Axsome Therapeutics, Inc.的 52 周低点为 75.56 美元，52 周高点为 152.94 美元。该公司的 50 日简单移动平均线为 136.66 美元，200 日简单移动平均线为 119.76 美元。该公司的市值为 75.2 亿美元，市盈率为-31.96，贝塔值为 0.48。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company had revenue of $170.99 million for the quarter, compared to analysts' expectations of $162.96 million. The firm's revenue was up 63.2% on a year-over-year basis. On average, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.</p>
<div class="lb-trans"><p>Axsome Therapeutics（NASDAQ:AXSM - 获取免费报告）最近在 11 月 3 日发布了季度财报。该公司报告本季度每股收益为（0.94 美元），低于市场共识预期的（0.82 美元）12 美分。Axsome Therapeutics 的净利润率为-40.90%，股本回报率为-277.31%。该公司本季度的收入为 1.7099 亿美元，而分析师预期为 1.6296 亿美元。该公司的收入同比增长 63.2%。平均而言，股票研究分析师预计 Axsome Therapeutics, Inc.在本年度将发布-2.79 的每股收益。</p>
</div><h2>About Axsome Therapeutics</h2>
<div class="lb-trans"><h2>关于 Axsome Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利安非特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的白天过度嗜睡的药物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Axsome Therapeutics</li>
<li>股息王宝洁在财报后疲软时值得买入</li>
<li>市场动能：3 只有望大幅突破的股票</li>
<li>成长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

景顺投资管理公司减少了其在 Axsome Therapeutics, Inc. $AXSM 的股份